Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Orchid Pharma's Enterprise Value is $305.65 Mil.
Orchid Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $3.81 Mil. Therefore, Orchid Pharma's EV-to-EBIT ratio for today is 80.16.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Orchid Pharma's Enterprise Value is $305.65 Mil.
Orchid Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $7.79 Mil. Therefore, Orchid Pharma's EV-to-EBITDA ratio for today is 39.25.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Orchid Pharma's Enterprise Value is $305.65 Mil.
Orchid Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $90.67 Mil. Therefore, Orchid Pharma's EV-to-Revenue ratio for today is 3.37.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Orchid Pharma's Enterprise Value is $305.65 Mil.
Orchid Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil. Therefore, Orchid Pharma's EV-to-FCF ratio for today is .
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Orchid Pharma (LUX:ORCHP) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Orchid Pharma's current Enterprise Value is $305.65 Mil.
Orchid Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.81 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Orchid Pharma's current Enterprise Value is $305.65 Mil.
Orchid Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.79 Mil.
Orchid Pharma's current Enterprise Value is $305.65 Mil.
Orchid Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $90.67 Mil.
Orchid Pharma's current Enterprise Value is $305.65 Mil.
Orchid Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Orchid Pharma's current Enterprise Value is $305.65 Mil.
Orchid Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchid Pharma Enterprise Value Related Terms
Orchid Pharma Enterprise Value Historical Data
* Premium members only.
The historical data trend for Orchid Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LUX:ORCHP vs ZTS, UTHR: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchid Pharma Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Orchid Pharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Orchid Pharma's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchid Pharma (LUX:ORCHP) has a Enterprise Value of $305.65 Mil as of Jun. 30, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Orchid Pharma and its competitors.
Is Orchid Pharma's Enterprise Value too high?
Orchid Pharma's current Enterprise Value is $305.65 Mil. Overall, Orchid Pharma has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's Enterprise Value compare to ZTS and UTHR?
Orchid Pharma's Enterprise Value of $305.65 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Orchid Pharma and its competitors. Orchid Pharma's current Enterprise Value is $305.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Orchid Pharma (LUX:ORCHP) has a current Enterprise Value of $305.65 Mil. The stock's GF Value™ is $4.60, compared to a current price of $5.45 — trading 18.5% above its estimated fair value. The current Enterprise Value is $305.65 Mil. Orchid Pharma's overall GF Score™ is 60/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Orchid Pharma (LUX:ORCHP), the current Enterprise Value is $305.65 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchid Pharma (LUX:ORCHP) Overvalued in 2026?
Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued.
The current stock price of $5.45 is trading 18.5% above its estimated GF Value™ of $4.60.
Key valuation signals for LUX:ORCHP:
Enterprise Value: $305.65 Mil
GF Value™: $4.60 vs. price of $5.45 (18.5% above fair value)
No single metric tells the full story. See the LUX:ORCHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
60GF Score
Get the complete analysis for LUX:ORCHP
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ORCHP has been successfully added to your 
